Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | MAPT | P10636 | 4/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | CES2 | O00748 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.43 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.42 |
| ▸ | TXNRD3 | Q86VQ6 | 1/20 | 0.42 |
| ▸ | TXNRD2 | Q9NNW7 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4019895 | 1.00 | ALDH1A1 (0.51) | ALDH1A1MAPTKMT2AMAPK1TDP1 | |
| SCHEMBL5517865 | 0.85 | ERN1 (0.47) | ALDH1A1MAPTKMT2AMAPK1HTT | |
| SCHEMBL25299940 | 0.84 | ALDH1A1 (0.50) | ALDH1A1MAPTKMT2AMAPK1TDP1 | |
| SCHEMBL3019574 | 0.84 | ALDH1A1 (0.42) | ALDH1A1MAPTKMT2AMAPK1TDP1 | |
| SCHEMBL3019577 | 0.84 | ALDH1A1 (0.42) | ALDH1A1MAPTKMT2AMAPK1TDP1 | |
| SCHEMBL3019575 | 0.84 | ALDH1A1 (0.42) | ALDH1A1MAPTKMT2AMAPK1TDP1 | |
| SCHEMBL9551016 | 0.82 | MAPT (0.56) | ALDH1A1MAPTKMT2AMAPK1TDP1 | |
| SCHEMBL9358684 | 0.82 | ERN1 (0.59) | ALDH1A1MAPTKMT2AMAPK1TDP1 | |
| SCHEMBL9358680 | 0.82 | ERN1 (0.59) | ALDH1A1MAPTKMT2AMAPK1TDP1 | |
| SCHEMBL9384129 | 0.82 | MAPT (0.56) | ALDH1A1MAPTKMT2AMAPK1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8227469-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2012-07-24 | — | — | US | disclosed |
| US-20090197879-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | BALAN CHENERA | 2009-08-06 | — | — | US | disclosed |
| US-7534798-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2009-05-19 | — | — | US | disclosed |
| EP-1745034-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2007-01-24 | — | — | EP | disclosed |
| WO-2005077938-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2005-08-25 | — | — | WO | disclosed |
| US-20050182067-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN, INC. | 2005-08-18 | — | — | US | disclosed |
| EP-1146083-B1 | USE OF A RESIN MATERIAL FOR ELECTRICAL INSULATING AND ELECTRIC WIRE AND CABLE USING THE SAME | JAPAN POLYOLEFINS CO LTD (JP) | 2005-01-05 | — | — | EP | disclosed |
| US-6479590-B1 | Electrical insulating resin material, electrical insulating material, and electric wire and cable using the same | JAPAN POLYOLEFINS CO., LTD. (JP) | 2002-11-12 | — | — | US | disclosed |
| EP-1146083-A1 | ELECTRICAL INSULATING RESIN MATERIAL, ELECTRICAL INSULATING MATERIAL, AND ELECTRIC WIRE AND CABLE USING THE SAME | Japan Polyolefins Co., Ltd. (JP) | 2001-10-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090197879-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | TRPV1, TRPV2, TRPV3 | ALDH1A1 3238/4885MAPT 755/4885KMT2A 3777/4885 |
| US-20050182067-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV2, TRPV3 | ALDH1A1 3238/4885MAPT 755/4885KMT2A 3777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.